Pfizer and Bristol-Myers Squibb (BMS) are collaborating to provide grant support for continuing professional education in the areas of atrial fibrillation and venous thromboembolism. We are committed to supporting innovative, independent medical education for healthcare professionals. Grants via this collaboration will be funded by Pfizer, but reviewed and approved by both companies.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: April 1, 2021
Geographic Scope: Global (excluding United States)
Clinical Area: Atrial Fibrillation/Venous Thromboembolism
Link to full RFP: Atrial Fibrillation and Venous Thromboembolism
Application Due Date: Application Cycles - please see RFP documentation
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on improving the care of patients by addressing knowledge gaps in either Atrial Fibrillation (AF) or Venous Thromboembolism (VTE) or both areas.